Page 396 - Read Online

Gironés et al. Age-related efficacy of treatment in metastatic NSCLC

lung cancer in elderly patients. Efforts to prevent the 12. Pallis AG, Gridelli C, Wedding U, Faivre-Finn C, Veronesi G,
initiation of the smoking habit and also to quit smoking Jaklitsch M, Luciani A, O’Brien M. Management of elderly patients
should be made, regardless of age. with NSCLC; updated expert’s opinion paper: EORTC elderly task
force, Lung Cancer Group and International Society for Geriatric
Oncology. Ann Oncol 2014;25:1270-83.
Financial support and sponsorship 13. Weiss J, Langer C. Treatment of lung cancer in the elderly patient.
Nil. Semin Respir Crit Care Med 2013;34:802-9.
14. D’Addario G, Pintilie M, Leighl NB, Feld R, Cerny T, Shepherd
Conflicts of interest FA. Platinum-based versus non-platinum-based chemotherapy in
There are no conflicts of interest. advanced non-small-cell lung cancer: a meta-analysis of the published
literature. J Clin Oncol 2005;23:2926-36.
Patient consent 15. Gridelli C, Gallo C, Shepherd FA, Illiano A, Piantedosi F, Robbiati SF,
Obtained. Manzione L, Barbera S, Frontini L, Veltri E, Findlay B, Cigolari S,
Myers R, Ianniello GP, Gebbia V, Gasparini G, Fava S, Hirsh V, Bezjak
A, Seymour L, Perrone F.Gemcitabine plus vinorelbine compared with
Ethics approval cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced
Ethics approval was obtained prior to the non-small-cell lung cancer: a phase III trial of the Italian GEMVIN
commencement of the study. Investigators and the National Cancer Institute of Canada Clinical
Trials Group. J Clin Oncol 2003;21:3025-34.
REFERENCES 16. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook
J, Zhu J, Johnson DH; Eastern Cooperative Oncology Group.
Comparison of four chemotherapy regimens for advanced non-small
1. Alberg AJ, Brock MV, Ford JG, Samet JM, Spivack SD. Epidemiology cell lung cancer. N Engl J Med 2002;346:92-8.
of lung cancer: diagnosis and management of lung cancer, 3rd ed:
American College of Chest Physicians evidence-based clinical 17. Effects of vinorelbine on quality of life and survival of elderly patients
with advanced non-small-cell lung cancer. The Elderly Lung Cancer
practice guidelines. Chest 2013;143:e1S-29S.
2. Hurria A, Browner IS, Cohen HJ, Denlinger CS, deShazo M, Vinorelbine Italian Study Group. J Natl Cancer Inst 1999;91:66-72.
Extermann M, Ganti AK, Holland JC, Holmes HM, Karlekar MB, 18. Frasci G, Lorusso V, Panza N, Comella P, Nicolella G, Bianco A, De
Keating NL, McKoy J, Medeiros BC, Mrozek E, O’Connor T, Cataldis G, Iannelli A, Bilancia D, Belli M, Massidda B, Piantedosi
Petersdorf SH, Rugo HS, Silliman RA, Tew WP, Walter LC, Weir F, Comella G, De Lena M. Gemcitabine plus vinorelbine versus
AB 3rd, Wildes T. Senior adult oncology. J Natl Compr Canc Netw vinorelbine alone in elderly patients with advanced non-small-cell
2012;10:162-209. lung cancer. J Clin Oncol 2000;18:2529-36.
3. Sacher AG, Le LW, Leighl NB, Coate LE. Elderly patients with 19. Gridelli C, Perrone F, Gallo C, Cigolari S, Rossi A, Piantedosi
advanced NSCLC in phase III clinical trials: are the elderly excluded F, Barbera S, Ferraù F, Piazza E, Rosetti F, Clerici M, Bertetto O,
from practice-changing trials in advanced NSCLC? J Thorac Oncol Robbiati SF, Frontini L, Sacco C, Castiglione F, Favaretto A, Novello
2013;8:366-8. S, Migliorino MR, Gasparini G, Galetta D, Iaffaioli RV, Gebbia
4. Davidoff AJ, Tang M, Seal B, Edelman MJ. Chemotherapy and V; MILES Investigators. Chemotherapy for elderly patients with
survival benefit in elderly patients with advanced non-small-cell lung advanced non-small-cell lung cancer: the Multicenter Italian Lung
cancer. J Clin Oncol 2010;28:2191-7. Cancer in the Elderly Study (MILES) phase III randomized trial. J
5. Beckett P, Callister M, Tata LJ, Harrison R, Peake MD, Stanley Natl Cancer Inst 2003;95:362-72.
R, Woolhouse I, Slade M, Hubbard RB. Clinical management of 20. Kudoh S, Takeda K, Nakagawa K, Takada M, Katakami N, Matsui
older people with non-small cell lung cancer in England. Thorax K, Shinkai T, Sawa T, Goto I, Semba H, Seto T, Ando M, Satoh T,
2012;67:836-9. Yoshimura N, Negoro S, Fukuoka M. Phase III study of docetaxel
6. Sim SH, Kim YJ, Kim SH, Keam B, Kim TM, Lee SH, Kim DW, Heo compared with vinorelbine in elderly patients with advanced non-
DS, Lee JS. Current status of chemotherapy use and clinical outcome small-cell lung cancer: results of the West Japan Thoracic Oncology
in octogenarians with advanced non-small cell lung cancer. J Cancer Group Trial (WJTOG 9904). J Clin Oncol 2006;24:3657-63.
Res Clin Oncol 2015;14:1073-81. 21. Quoix E, Zalcman G, Oster JP, Westeel V, Pichon E, Lavolé A, Dauba
7. Firat S, Pleister A, Byhardt RW, Gore E. Age is independent of J, Debieuvre D, Souquet PJ, Bigay-Game L, Dansin E, Poudenx
comorbidity influencing patient selection for combined modality M, Molinier O, Vaylet F, Moro-Sibilot D, Herman D, Bennouna J,
therapy for treatment of stage III nonsmall cell lung cancer (NSCLC). Tredaniel J, Ducoloné A, Lebitasy MP, Baudrin L, Laporte S, Milleron
Am J Clin Oncol 2006; 29:252-7. B; Intergroupe Francophone de Cancérologie Thoracique. Intergroupe
8. Wisnivesky JP, Strauss GM. Treating elderly patients with stage III Francophone de Cancérologie Thoracique. Carboplatin and weekly
NSCLC. Lancet Oncol 2012;13:650-1. paclitaxel doublet chemotherapy compared with monotherapy in
9. Wang S, Wong ML, Hamilton N, Davoren JB, Jahan TM, Walter elderly patients with advanced non-small-cell lung cancer: IFCT-0501
LC. Impact of age and comorbidity on non-small-cell lung cancer randomised, phase 3 trial. Lancet 2011;378:1079-88.
treatment in older veterans. J Clin Oncol 2012;30:1447-55. 22. Ettinger DS, Akerley W, Borghaei H, Chang AC, Cheney RT, Chirieac
10. Blanco JAG, Toste IS, Alvarez RF, Cuadrado GR, Gonzalvez AM, LR, National comprehensive cancer network. Non-small cell lung
Martín IJG. Age, comorbidity, treatment decision and prognosis in cancer, version 2, 2013. J Natl Compr Canc Netw 2013;11:645-53.
lung cancer. Age Ageing 2008;37:715-8. 23. Travis WD, Brambilla E, Müller-Hermelink HK, Harris CC. Pathology
11. de Rijke JM, Schouten LJ, Velde ten GPM, Wanders SL, Bollen EC, and genetics of tumours of the lung, pleura, thymus and heart. Lyon:
Lalisang RI, van Dijck JA, Kramer GW, van den Brandt PA. Influence IARC Press: 2004.
of age, comorbidity and performance status on the choice of treatment 24. Bach PB, Kattan MW, Thornquist MD, Kris MG, Tate RC, Barnett MJ,
for patients with non-smallcell lung cancer; results of a population- Hsieh LJ, Begg CB. Variations in lung cancer risk among smokers. J
based study. Lung Cancer 2004;46:233-45. Natl Cancer Inst 2003;95:470-8.
386 Journal of Cancer Metastasis and Treatment ¦ Volume 2 ¦ September 30, 2016